The expression of NAD(P)H:quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 6, 2007, Pages 2346-2352

  Palming, Jenny ^a   Sjöholm, Kajsa ^a,c   Jernås, Margareta ^a   Lystig, Theodore C ^a   Gummesson, Anders ^a   Romeo, Stefano ^b   Lönn, Lars ^a   Lönn, Malin ^a   Carlsson, Björn ^a   Carlsson, Lena M S ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; DNA; GLUCOSE; INSULIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ARTICLE; CELL ISOLATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DNA MICROARRAY; ENZYME REGULATION; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT REDUCTION;

MUS;

EID: 34347266584     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2476     Document Type: Article

References (40)

1. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D 2000 NAD(P)H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 129:77-97
2. Gaikwad A, Long II DJ, Stringer JL, Jaiswal AK 2001 In vivo role of NAD(P)H: quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J Biol Chem 276:22559-22564
3. Joseph P, Xie T, Xu Y, Jaiswal AK 1994 NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res 6:525-532
4. Benson AM, Hunkeler MJ, Talalay P 1980 Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 77:5216-5220
5. Siegel D, McGuinness SM, Winski SL, Ross D 1999 Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9:113-121
6. Martin LF, Patrick SD, Wallin R 1987 DT-diaphorase in morbidly obese patients. Cancer Lett 36:341-347
7. Siegel D, Franklin WA, Ross D 1998 Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4:2065-2070
8. Sjöholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, Lystig TC, Jennische E, Brandberg J, Torgerson JS, Carlsson B, Carlsson LM 2005 A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 90:2233-2239
9. Sjöholm K, Palming J, Lystig TC, Jennische E, Woodruff TK, Carlsson B, Carlsson LM 2006 The expression of inhibin beta B is high in human adipocytes, reduced by weight loss, and correlates to factors implicated in metabolic disease. Biochem Biophys Res Commun 344:1308-1314
10. Jernås M, Palming J, Sjöholm K, Jennische E, Svensson PA, Gabrielsson BG, Levin M, Sjögren A, Rudemo M, Lystig TC, Carlsson B, Carlsson LM, Lönn M2006 Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J 20:1540-1542
11. Smith U, Sjöström L, Björntorp P 1972 Comparison of two methods for determining human adipose cell size. J Lipid Res 13:822-824
12. Gabrielsson BG, Johansson JM, Jennische E, Jernås M, Itoh Y, Peltonen M, Olbers T, Lönn L, Lönroth H, Sjöström L, Carlsson B, Carlsson LM, Lönn M 2002 Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes Res 10:608-616
13. Sjöström L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, Hallgren P, Jonsson E, Karlsson J, Lapidus L, Lindroos A-K, Lindstedt S, Lissner L, Narbro K, Näslund I, Olbe L, Sullivan M, Sylvan A, Wedel H, Ågren G 1992 Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord 16:465-479
14. Eckel RH, Grundy SM, Zimmet PZ 2005 The metabolic syndrome. Lancet 365:1415-1428
15. Berg CM, Lissner L, Aires N, Lappas G, Toren K, Wilhelmsen L, Rosengren A, Thelle DS 2005 Trends in blood lipid levels, blood pressure, alcohol and smoking habits from 1985 to 2002: results from INTERGENE and GOTMONICA. Eur J Cardiovasc Prev Rehabil 12:115-125
16. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH 2004 Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395
17. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH 2004 The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 93:1473-1480
18. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
19. Zeger SL, Liang KY 1986 Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121-130
20. Rotnitzky A, Jewell NP 1990 Hypothesis testing of regression parameters in semiparametric generalized linear models for cluster correlated data. Biometrika 77:485-497
21. Browning JD, Horton JD 2004 Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147-152
22. Marchesini G, Marzocchi R, Agostini F, Bugianesi E 2005 Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16:421-427
23. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, Hisatomi A, Ozaki I, Yamamoto K, Kitajima Y, Kawaguchi Y, Kuroki S, Ono N 2006 Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol 41:462-469
24. Goldstein DJ 1992 Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16:397-415
25. Nomura F, Ohnishi K, Ochiai T, Okuda K 1987 Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet. Radiology 162:845-847
26. Björntorp P, Sjöström L 1972 The composition and metabolism in vitro of adipose tissue fat cells of different sizes. Eur J Clin Invest 2:78-84
27. Farnier C, Krief S, Blache M, Diot-Dupuy F, Mory G, Ferre P, Bazin R 2003 Adipocyte functions are modulated by cell size change: potential involvement of an integrin/ERK signalling pathway. Int J Obes Relat Metab Disord 27:1178-1186
28. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE 2000 Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 43:1498-1506
29. Rudich A, Kozlovsky N, Potashnik R, Bashan N 1997 Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol 272:E935-E940
30. Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K, Maruyama N, Kitagawa N, Tanaka T, Hori Y, Nakatani K, Yano Y, Adachi Y 2003 Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 88:4673-4676
31. Evans JL, Goldfine ID, Maddux BA, Grodsky GM 2002 Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599-622
32. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, Prabhala A, Afzal A, Garg R 2001 The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 86:355-362
33. Dandona P, Aljada A, Bandyopadhyay A 2004 Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7
34. Sell H, Dietze-Schroeder D, Eckel J 2006 The adipocyte-myocyte axis in insulin resistance. Trends Endocrinol Metab 17:416-422
35. Garg A 2004 Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234
36. Wang G, Zhang L, Li Q 2006 Genetic polymorphisms of GSTT1, GSTM1, and NQO1 genes and diabetes mellitus risk in Chinese population. Biochem Biophys Res Commun 341:310-313
37. Björntorp P 1991 Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143
38. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M 2004 Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 39:754-763
39. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, Croce LS, Paoletti S, de Bernard B, Tiribelli C, Dalla Palma L 1997 Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 27:108-113
40. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, de Bernard B, Tiribelli C, Dalla Palma L 1995 Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 5:281-285